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Transgenic zebrafish embryos expressing tissue-
specific green fluorescent protein (GFP) can provide
an unlimited supply of primary embryonic cells.
Agents that promote the differentiation of these cells
may be beneficial for therapeutics. We report a high-
throughput approach for screening small molecules
that regulate cell differentiation using lineage-
specific GFP transgenic zebrafish embryonic cells.
After validating several known regulators of thediffer-
entiation of endothelial and other cell types, we per-
formed a screen for proangiogenic molecules using
undifferentiated primary cells from flk1-GFP trans-
genic zebrafish embryos. Cells were grown in 384-
well plates with 12,128 individual small molecules,
and GFP expression was analyzed by means of an
automated imaging system, which allowed us to
screen thousands of compounds weekly. As a result,
23 molecules were confirmed to enhance angiogen-
esis, and 11 of them were validated to promote the
proliferation of mammalian human umbilical vascular
endothelial cells and induce Flk1+ cells from murine
embryonic stem cells. We demonstrated the general
applicability of this strategy by analyzing additional
cell lineages using zebrafish expressing GFP in
pancreatic, cardiac, and dopaminergic cells.
INTRODUCTION
In the past decade, the zebrafish has emerged as a viable model
organism for bioactive small-molecule discovery. Using zebra-
fish, it is now possible to assess the specificity, efficacy, and
toxicity of smallmolecules in thecontext of liveanimals. Zebrafish
and mammals have a similar genetic and tissue/organ makeup.
Thus, small molecules discovered in zebrafish screens often
have analogous effects in mammalian systems, and vice versa
(Lally et al., 2007; Murphey et al., 2006; Patton and Zon, 2001;
Peterson et al., 2000, 2004; Stern and Zon, 2003; Zon and
Peterson, 2005). For instance, a chemical screen targeting theCelBmp pathway used a chemical library of 7,500 compounds to
identify dorsomorphin, a molecule that has conserved inhibitory
activity on Bmp type I receptors alk2, alk3, and alk7, and has
dorsalizing effects on zebrafish embryos (Yu et al., 2008).
Although they are impressive in terms of screening capacity as
a vertebrate model, zebrafish embryonic assays still cannot
match the scale and speed of cell culture assays. To overcome
this limitation, we developed an automated analysis of cultured
primary cell differentiation as a strategy to preselect bio-
active candidate compounds for further analysis (Figure 1). This
strategy uses genetically stable, lineage-specific green fluo-
rescent protein (GFP) transgenic zebrafish embryos at the blas-
tula/gastrula stages to generate pluripotent primary cells, and
allows them to differentiate in vitro. This culture system is equiv-
alent to mammalian embryonic stem cells and can be used to
screen tens of thousands of small-molecule compounds or
peptide agents for effects on GFP-expressing/differentiating
cell populations. Positive compounds from this primary screen
can then be rescreened using mammalian assays and intact
embryos.
RESULTS
Reproducible Fluorescent Protein Expression
of Transgenic Lineages in Primary Cell Culture
To visualize the differentiation of different cell lineages marked
by fluorescent protein expression in primary culture, we used
several transgenic lines expressing GFP or red fluorescent
protein (RFP) in various cell types representing the mesoderm,
endoderm, and ectoderm. These fish included stable transgenic
lines expressing GFP or RFP under the regulatory sequences of
flk1 (Kdrl) for vascular endothelial cells, gata1 and scl for hema-
topoietic cells, cmlc2 for cardiac myocytes, mlc for skeletal
muscle, insulin for pancreatic endocrine beta cells, and vmat2
for dopaminergic/vesicular monoamine transporter 2-positive
neurons. Embryos from each of these transgenic lines were
collected at late blastula/early gastrula stages and dissociated
to generate primary cells. The dissociated embryonic cells,
which initially expressed no fluorescent proteins due to their
undifferentiated status, were plated into multiwell plates and
allowed to grow in L15 basic medium for 5–9 days. Most of the
primary cells became attached to the bottom of the plate withinl Reports 2, 695–704, September 27, 2012 ª2012 The Authors 695
Figure 1. Overall Strategy of Primary-
Cell-Based High-Throughput Screening
for Bioactive Small Molecules Using Cells
Dissociated from Early Transgenic Zebra-
fish Embryos24 hr of culture. At the same time, a small but relatively stable
percentage of cells in culture started to express transgenic fluo-
rescent protein. Under our culture conditions, lineage-specific
cells acquired characteristic features of cellular differentiation.
For vascular endothelial cell differentiation, flk1-GFP trans-
genic embryonic cells initially showed GFP expression after
24 hr of culture and individual cells appeared scattered. At day
2, flk1-GFP-expressing cells became elongated and clustered
together to form network-like structures. At days 3 and 4, flk1-
GFP positive cells formed more extensive tube-like networks.
These GFP-expressing cells underwent apoptosis and disap-
peared after 6 days of culture (Figure 2).
For hematopoietic cell differentiation, we used two fluorescent
proteins to colabel different stages of differentiation. Gata1 is696 Cell Reports 2, 695–704, September 27, 2012 ª2012 The Authorsa marker for erythroid progenitors and
differentiated primitive red blood cells,
whereas Scl, a bHLH transcription factor,
is expressed in both hematopoietic and
vascular progenitor cells, as well as in
some neurons (Zhang and Rodaway,
2007). Double-fluorescent transgenic
embryos carrying transgenes for gata1-
dsRed and scl-GFP were dissociated at
the late blastula stage to allow visualiza-
tion of hematopoietic cell differentiation
in primary culture. We observed scl-GFP
and gata1-dsRed expression from day 2
to day 9 of primary culture (Figure S1).
Consistent with gene expression profiling
in vivo, scl-GFP and gata1-dsRed were
coexpressed in round-shaped hemato-
poietic progenitor cells (Figures S1A–
S1C, A for bright field, white arrowheads)
and were also uniquely expressed in
some non-round cells (Figure S1B, red
arrowheads), which are presumably Scl-
positive neuronal cells and Gata1-posi-
tive red blood cells (Figure S1C, blue
arrowheads). Of note, gata1-dsRed-
expressing round-shaped cells survived
until day 9 and clustered into colony-like
structures (Figures S1D and S1F, white
circle and red cells) in which some
cells showed colocalized expression of
gata1-dsRed and scl-GFP (Figures S1E
and S1F, white arrowheads).
For myocardial differentiation marked
by cmlc2-GFP expression, cultured pri-
mary cells began to express GFP at day
2 and continued until day 5. Some of
the cells became contractile, resemblingcardiac cells (Figures S1G–S1J). The skeletal-muscle-specific
mlc-GFP maintained its expression from day 2 to day 4 and
showed a morphological resemblance to skeletal muscle cells
(Figures S1K, S1L, and S1N, and bright fieldM for N). For pancre-
atic beta cell differentiation, marked by insulin-GFP expression,
low-frequency but clearly detectable GFP-positive cells became
visible after 24 hr of culture (Figure S2A). Treatment of these
primary cells with 1 mM retinoic acid (RA) increased the number
of insulin-GFP expressing cells by 10-fold (Figure S2C)
compared with the control (B) at day 2. This low frequency of
GFP-positive cells in untreated primary cells provides a consis-
tent baseline for detecting agents that can increase the differen-
tiation of pancreatic beta cells, as demonstrated by the effects
of RA treatment (Figure S2). For vmat2-GFP-positive neurons,
Figure 2. Differentiation of flk1-GFP-Labeled Endothelial Cells in Primary Culture
Flk1-GFP expressing endothelial cells are scattered at day 1 and become flatten and elongated at days 2–4, undergoing tube formation. After 5–6 days of culture,
GFP-positive cells start to die (blue circles).
(A and B) Primary cells stained by (A) DIC and (B) Hoechst 33342 (5 mg/ml for 4.5–5 hr) on day 6.
See also Figures S1 and S2.2% of cells were GFP-positive after 48 hr of culture (Fig-
ure S2D). Basic fibroblast growth factor (bFGF) promoted the
generation of vmat2-GFP-labeled neurons and suppressed the
differentiation of pigment cells (Figures S2E and S2G) compared
with the untreated control (Figures S2D and S2F). There is a lack
of zebrafish lines with faithful GFP expression specifically in
dopaminergic neurons. Thus, our vmat2-GFP line can be useful
for studying in vitro differentiation of dopaminergic neurons.
Response of Endothelial GFP Expression to Regulatory
Agents in Primary Cell Culture
TheFGFand vascular endothelial growth factor (VEGF) pathways
are critical for vasculogenesis and angiogenesis in both develop-
ment and pathological conditions (Cross and Claesson-Welsh,
2001; Poole et al., 2001). Recombinant FGF has been reported
to induce VEGF expression and proliferation in human umbilicalCelvascular endothelial cells (HUVECs) via both autocrine and para-
crine mechanisms (Parsons-Wingerter et al., 2000; Seghezzi
et al., 1998). To investigate whether exogenous growth factors
can promote endothelial differentiation in zebrafish primary
embryonic cell culture, we supplemented the culture medium
with recombinant bFGF and VEGF. At 100 ng/ml, bFGF signifi-
cantly stimulated flk1-GFP expression at day 1 of culture (Figures
3A–3D). Moreover, recombinant human VEGF121 significantly
stimulated endothelial growth (Figure 3; p = 0.0007), consistent
with previous reports that recombinant VEGF121 remarkably
enhanced sprout formation and vessel length in HUVECs
(Nakatsu et al., 2003). SB-431542 is a potent and specific inhib-
itor of the transforming growth factor-b (TGFb) superfamily type I
activin receptor-like kinase (Alk) receptors Alk4, Alk5, and
Alk7, which are involved in many biological activities, including
cell growth, differentiation, migration, survival, and adhesion.l Reports 2, 695–704, September 27, 2012 ª2012 The Authors 697
Figure 3. Flk1-GFP-Labeled Endothelial Cells Respond to Growth Factors and Small Molecules in Primary Culture
(A–I) Endothelial cell proliferation and differentiation derived from Flk1-GFP are significantly promoted by 100 ng/ml bFGF (C, bright field, and D) compared with
control (A, bright field, and B) at 22 hr after culture. Recombinant VEGF121 (20 ng/ml, F), small molecule SB-431542 (2 mM,G) and the combination of both (H) also
remarkably enhance Flk1-GFP endothelial tube formation compared with control (E) at day 5, which exhibits a significant increase in total tube length (I-1, control;
I-2, 2 mM SB431542; I-3, 20 ng/ml VEGF121; I-4, 2 mM SB431542 and 20 ng/ml VEGF121). The number values represent total tube length.
See also Figure S3.Furthermore, the TGFb/ALK5 pathwaywas found to inhibit endo-
thelial cell migration and proliferation in vitro (Goumans et al.,
2002). SB-431542 therefore acts to stimulate proliferation, differ-
entiation, and vessel formation in endothelial cells derived from
embryonic stem cells or from fetal mouse metatarsals (mouse
metatarsal assays), when treated alone or in combination with
VEGF (Liu et al., 2009; Watabe et al., 2003). Similarly, we
observed that SB-431542 stimulated tube formation in flk1-
GFP-labeled endothelial cells in primary culture at day 5 when
cultured alone (Figures 3G and 3I, lane 2) or with VEGF (Figures
3H and 3I, lane 4). Compared with DMSO, SB-431542 increased
the total tube lengths 3-fold and the number of branch points
2-fold. This finding suggests that SB-431542 can be used as
a positive control for identifying other small molecules that can
promote vascular differentiation in zebrafish primary cell culture.
To validate that the increasedGFPexpression represents endog-
enous gene expression, we analyzed flk1 mRNA by quantitative
PCR (qPCR), and found that SB-431542 increased its level by
2.2-fold.
The above results suggest that cultured primary cells are
capable of responding to positive stimuli under culture condi-
tions. We next tested whether flk1-GFP expression in primary
culture would respond to inhibitory molecules. SU5416, a potent
inhibitor of VEGFR2 signaling, has been widely used to inhibit
angiogenesis in vivo and in vitro (Fong et al., 1999; Serbedzija
et al., 1999). Consistent with previous reports, SU5416 markedly
inhibited the growth and migration of endothelial cells labeled698 Cell Reports 2, 695–704, September 27, 2012 ª2012 The Authorwith flk1-GFP in primary culture (Figures S3A–S3D). In addition,
SU5416 suppressed bFGF-induced endothelial cell growth at
24 hr after culture (Figures S3E–S3L), indicating that the FGF
signaling pathway promotes proliferation and differentiation of
endothelial cells through the VEGF signaling pathway. Overall,
these studies demonstrate that primary cell cultures from trans-
genic zebrafish embryos expressing cell lineage-specific GFP
or RFP can be used to test either inductive or inhibitory agents,
ranging from small molecules to proteins, for the discovery of
potential therapeutic drugs.
High-Throughput Screening for Proangiogenic
Compounds in flk1-GFP Primary Culture
Investigators have made a tremendous effort to identify angio-
genesis inhibitors for their potential application in cancer thera-
peutics. However, much less attention has been directed to
the identification of proangiogenic drugs for treating diseases
such as chronic wounds and peripheral arterial and ischemic
heart diseases. In such conditions, the therapeutic goal is to
stimulate angiogenesis to improve the delivery of survival factors
to sites of tissue repair, mobilize regenerative stem cells, and ulti-
mately restore function to the tissues. With the use of our flk1-
GFP cultured cell assay, we were able to perform a large-scale
screen for proangiogenic small molecules. Primary cells pre-
pared from flk1-GFP transgenic embryos were seeded onto
384-well plates and treated with compounds. Images of flk1-
GFP-labeled endothelial cells were taken with an automatics
Table 1. Ratios of Selected Positive Hits to SB 431542 in Total Tube Length and Number of Branch Points
Chemicals SB A48 Nd DTR SST A46 A36 A33 A93 A79 Lh ZDM A69 A54
Ratio in total tube length 1 1.5 1.5 1.5 1.6 1.7 1.7 1.7 1.7 1.8 1.8 1.8 1.8 1.8
Ratio in branch point 1 1.6 1.6 1.7 1.5 1.7 1.7 1.8 1.8 1.6 1.6 1.7 1.9 2
Chemicals SB A39 A80 A14 Gh ADT Fh MH5 A62 A86 A65 Dip Rl Ph
Ratio in total tube length 1 1.8 1.8 1.9 1.9 1.9 2 2 2.1 2.1 2.3 2.4 2.5 2.6
Ratio in branch point 1 2 2.1 1.7 1.8 2.1 1.8 2 1.5 2.3 2.5 3 2.8 2.4
Chemicals used: A14, AST 6156114; A33, AST 6953386; A36, AST 6541036; A39, AST 06978839; A46, AST 6978646; A48, AST 5546348; A54, AST
7153654; A62, AST 6417262; A65, AST 6953065; A69, AST 5062069; A79, AST 6291379; A80, AST 6014780; A86, AST 6978186; A93, AST 5557493;
ADT, androsterone; Dip, dipyridamole; DTR, DTR815; Fh, fenoterol hydrobromide; Gh, guanfacine hydrochloride; Lh, levamisole hydrochloride; MH5,
methylhydantoin-5-(D); Nd, nimodipine; Ph, papaverine hydrochloride; Rl, rolipram; SB, SB431542; SST, succinylsulfathiazole; ZDM, zimelidine
dihydrochloride monohydrate.fluorescence analyzer at day 5 of culture. A representative image
of a 384-well plate is shown in Figure S4, with column 2 as a posi-
tive control and column 23 as a negative control. We observed
a clear difference in tube-like endothelial cells between the two
columns (Figure S4). We developed an algorithm that measures
the total tube length and branch points to identify the positive
compounds (see Experimental Procedures; Table 1). The relative
ratios of total tube length and branch points between ex-
perimental compounds and controls were used to determine
whether a compound was positive for promoting angiogenesis.
For each plate, the average value of the column containing SB-
431542 served as a positive control.
Four commercially available libraries (Biomol, Prestwick,
Microsource, and Tar) containing 12,128 compounds were
selected for screening. Small molecules that induced total
vascular tube lengths and number of branch points equal to or
greater than those observed with SB-431542 treatment were
considered as positive hits, which yielded 165 candidate com-
pounds. These candidates were rescreened and 63% of
them still passed the initial screening criteria. Candidates that
demonstrated 1.5-fold greater vascular tube lengths and num-
bers of branch points than SB 431542 treatment were selected
for further analysis. This more-stringent criterion yielded 26
compounds (Table 1). Figure 4 shows representative images of
enhanced endothelial proliferation and tube formation by candi-
date compounds at day 5 of culture.
Validation of Candidate Compounds inMammalian Cells
and In Vivo
To determine whether the candidate compounds also promoted
the growth of mammalian endothelial cells, we examined their
activities in HUVEC assays.We tested 23 commercially available
candidates via a thiazolyl blue tetrazolium bromide (MTT) assay
and found that 11 of them enhanced the proliferation of HUVECs
by 19%–60%, with a p value of 0.02–0.000001 (Figure 5A). The
structures and names of these compounds are listed in Fig-
ure S5. Additionally, these compounds enhanced the migration
of HUVECs (Figures 5B–5E; only data for A65 are shown). Akt
(protein kinase B) signaling plays a major role in regulating endo-
thelial cellular proliferation, survival, migration, and adhesion,
and its activation by phosphorylation stimulates prolifera-
tion through multiple cell cycle targets (Chen et al., 2008;
Manning and Cantley, 2007). Hence, we selected six candidateCelcompounds (A65, A86, dipyridamole [Dip], fenoterol hydrobro-
mide [Fh], guanfacine hydrochloride [Gh], and succinylsulfa-
thiazole [SST]) and investigated their ability to modulate the
phosphorylation levels of Akt. HUVECs were treated with these
candidate compounds, followed by western blotting analysis
using an anti-phospho-Akt antibody. For all six compounds,
we observed increased phosphorylation of Akt compared with
DMSO-treated cells (Figures 5F, 5G, and S6A), suggesting that
the proangiogenic activities of these compounds involved Akt
signaling pathways. As a confirmation, we cotreated the cells
with wortmannin, a well-established inhibitor of the PI3K/Akt
pathway, and observed reversal of the proliferation effects of
HUVEC by the selected compounds (Figure S6B). Because
Akt-dependent phosphorylation has been implicated in acti-
vating endothelial nitric oxide (NO) synthase (eNOS), which
was found to be involved in cardiovascular homeostasis (Dimm-
eler et al., 1999), we sought to determine whether any of the
tested compounds exert their proangiogenic activity through
NO production. We conducted the same HUVEC proliferation
assays with selected compounds, adding the eNOS inhibitor
L-NAME (Hood and Granger, 1998). This assay showed that
the proproliferative effect of SST, Dip, Gh, and Fh on HUVEC
could be reversed by eNOS inhibition (Figure S6C), suggesting
that the Akt-eNOS pathway is involved in the mechanisms of
action for these compounds.
To determine whether these compounds could also induce
mammalian endothelial differentiation, we examined the ability
of the compounds to increase the number of Flk1+ cells gener-
ated from differentiating murine embryonic stem cells (mESCs).
We tested the 11 compounds that were able to promote the
growth of HUVEC cells by adding the compound to mESCs on
day 2 of differentiation and examining the level of Flk1 expres-
sion by flow cytometry on day 4 of differentiation (Figure 5H).
Contrary to its role in the promoting the proliferation of endothe-
lial cells, SB431542 inhibited the differentiation of mESCs into
Flk1+ cells. This result was expected because inhibition of
TGFb signaling promotes self-renewal and inhibits differentiation
in pluripotent cells (James et al., 2005). The 11 compounds
discovered in this work were all able to enhance the percentage
of Flk1+ cells over that of control conditions. A36, nimodipine
(Nd), and SST were all very consistent in their ability to increase
the percentage of Flk1+ cells by 50% (Figure 5H). Overall, these
findings validate that the effects of the small molecules identifiedl Reports 2, 695–704, September 27, 2012 ª2012 The Authors 699
Figure 4. Representative Images of Candidate Compounds that Promoted Endothelial Proliferation and Tube Formation at Day 5
(A) Control.
(B–D) Candidate compounds. i19, g6, e9, g12, d16, and d13, original plate well ID.
(E) 2 mM SB 431542.
(F–H) Candidate compounds. i19, g6, e9, g12, d16, and d13, original plate well ID.
See also Figures S4 and S5.from zebrafish embryo primary cell assays are largely conserved
in mammalian endothelial cells.
Intussusceptive angiogenesis, a mode of blood vessel forma-
tion and remodeling, occurs in lung and eye vasculature by
internal division of the preexisting capillary plexus without
sprouting (Djonov et al., 2000; Makanya et al., 2009). Therefore,
we next sought to investigate whether selected candidate
compounds could enhance angiogenesis in adult zebrafish, as
a test of proangiogenic activity in vivo. To that end, we treated
flk1-GFP transgenic adult fish with selected small molecules
and then observed the retinal vasculature after eye dissection
(Cao et al., 2010). As shown in Figure 6, two selected drugs—
SST and Dip—significantly enhanced retinal angiogenesis as
compared with the DMSO control treatment (n = 22 retinas).
SST and Dip increased the number of blood vessels by 27.2%
(p = 0.0216, n = 12 retinas) and 34.3% (p = 0.0220, n = 13 retinas),
and the vascular density by 49.8% (p = 0.0090, n = 12 retinas)
and 50.9% (p = 0.0250, n = 13 retinas), respectively.
DISCUSSION
The zebrafish has been established as an excellent vertebrate
system for studying embryonic development, modeling human
diseases, screening for pharmaceutical drugs, and dissecting
biological pathways. A key bottleneck in using zebrafish whole
animals for drug screening is the limitation of throughput. In
this work, we developed a primary-cell-based approach that
significantly expands the utility of this valuable model organism
by taking advantage of the vast collection of transgenic zebrafish
expressing GFP or RFP in specific tissues. Similarly to immortal-
ized-cell-based high-throughput screening, our approach offers
the advantage of high throughput, high content (with multicolor
transgenes), and high efficiency afforded by the screening of
small molecules. Given the fact that several pairs of fish can
produce thousands of eggs, a sufficient supply of embryos to
generate primary cells is never a limiting factor. A trained person700 Cell Reports 2, 695–704, September 27, 2012 ª2012 The Authorcan easily set up three 384-well plates per day. As shown above,
because primary cells differentiate in a time frame similar to
embryonic development, this method captures a biological
process in a way that is comparable to the zebrafish in vivo
screening system but can be scaled up significantly. In addition,
because it is difficult to visualize and quantify cells that are
deeply embedded within the zebrafish embryo, such as pancre-
atic b cells, whole-embryo compound screening is often ineffi-
cient. The use of primary cultured cells overcomes this limitation
by allowing direct visualization and statistical analysis of the cells
of interest.
We have shown that 11 out of 26 chemicals were capable of
enhancing the proliferation and migration of HUVECs, indicating
that a reasonable number of small molecules identified in our
zebrafish primary-cell-based screen could be translated into
the human endothelial system. In addition, these compounds
were able to promote the endothelial differentiation frommESCs.
For those compounds that failed to promote mammalian endo-
thelial cell proliferation and differentiation, it is likely that the
properties of their target proteins differ somewhat between
zebrafish and mammalian species. Further validating our finding
that 11 compounds showed positive hits in both zebrafish and
mammalian cells is the fact that several of these compounds
were previously implicated in promoting vascular formation.
Finger and Dunnett (1989) reported that Nd, a calcium channel
antagonist and a dilator of blood vessels, promoted vasculariza-
tion in suspension cell grafts in rats, although the drug had no
lasting effects on vascularization in intact brains. The authors
proposed that Nd may increase endothelial survival, reduce
loss of existing blood vessels, and stimulate existing vessels in
the nearby area to grow into the graft. Dip, a compound that
inhibits thrombus formation when given chronically, and causes
vasodilation when given at high doses over a short time, was
reported to induce capillary growth in normal and hypertrophic
hearts of rabbits (Torry et al., 1992). It was also observed to
enhance ischemic angiogenesis in the diabetic hind limb bys
Figure 5. Test of Candidate Compounds in Mammalian Cells
(A) Candidate compounds enhanced HUVEC proliferation significantly at 1 mM
or 10 mM (p = 0.0007, 0.005, 9.20E-05, 0.001, 1.40E-06, 0.021, 0.009, 2.70E-
05, 0.02, 0.02,1.00E-6, and 2.0E-04 for SB431542, A65, A79, A69, A86, A54,
A36, Gh, Nd, Dip, Fh, and SST, respectively) compared with 1% DMSO
control. Data from four independent experiments were analyzed.
(B–E) Candidate compounds enhanced HUVEC migration. HUVEC migration
was analyzed 24 hr after scratch wounds and drugswere added (B, C, D, and E
at 0 hr; B0, C0, D0, and E0 at 24 hr after treatment). Migration distances were
measured in micrometers and marked with white arrowheads.
Celpreferentially promoting endothelial proliferation in mice (Pattillo
et al., 2011). It is believed that elevated oxidative stress and
reduced NO bioavailability are hallmarks of endothelial cell
dysfunction and cardiovascular pathology during diabetes in
both humans and animals. Therefore, Dip was further character-
ized to enhance ischemia-induced angiogenesis and arterio-
genesis by increasing nitrite/NO production and decreasing
oxidative stress (Pattillo et al., 2011; Venkatesh et al., 2010).
Guanfacine, a a2-adrenoceptor agonist and vasodilator, was
shown to prevent the cardiovascular effects of hemispheric
ischemia by inducing a surge of luminal NO in rats (Figueroa
et al., 2001; Saad et al., 1986). Fh, a b2-adrenoceptor agonist,
was also found to induce NO production and eNOS phosphory-
lation in endothelial cells (Figueroa et al., 2009); however,
whether it could stimulate angiogenesis was not reported. None-
theless, these earlier reports are consistent with our finding that
the proproliferative effect of SST, Dip, Gh, and Fh onHUVECwas
reversible by eNOS inhibition. SST, an antibacterial drug, has not
previously been reported to enhance endothelial cell growth. It
will be interesting to determine whether this drug can be used
to treat vascular-deficiency diseases. It is worth mentioning
that five of these 11 compounds are FDA-approved drugs that
can be used directly in humans. For the rest of the compounds,
further studies of efficacy, pharmacokinetics, and safety are
needed to determine their application to angiogenesis-defi-
ciency diseases.
EXPERIMENTAL PROCEDURES
Preparation of Zebrafish Embryo Primary Cells
We used the following transgenic zebrafish lines or promoters: gata1-dsRed
(Long et al., 1997), scl-GFP (an enhancer trap line identified in-house) (Wen
et al., 2008), cmlc2-GFP, mlc-GFP, flk1-GFP, insulin-GFP (Huang et al.,
2001), and vmat2-GFP (Wen et al., 2008).
On day 1, 30 pairs of transgenic fish were set up with dividers in the
afternoon and released together tomate early the followingmorning. Collected
eggs were incubated at 32C in fish water containing 1X antibiotics (Antibiotic-
Antimycotic Solution; Cellgro). Later, at the gastrulation stage, embryos
were cleaned several times with Holtfreter’s solution that was prewarmed
at 32C.
Embryos were allowed to grow continuously to 80%epiboly/tailbud stage or
stage of interest at 32C. In the meantime, 20 ml of Leibovitz L15 medium
(phenol red free, 5% fetal bovine serum [FBS], 1% antibiotics) was added to
each of 384 wells of the Greiner mClear Black Plate (T-3037-9, ISC Bioexpress;
Greiner Bio-One) using a multichannel pipette in a sterile tissue culture hood.
To each well, compound (normally 10 mM) was then individually added via an
automated liquid handler. The entire columns of 2 and 23 for a 384-well plate
were reserved as positive (2 mM SB-431542) and negative (1% DMSO)
controls, respectively.(F) Akt phosphorylation levels increased in HUVECs by candidate compounds.
Akt phosphorylation assay was performed using HUVECs treated with
candidate small molecules for 8 hr (A65, A86, Dip, and Fh) and positive
compound (SB) compared with DMSO control.
(G) Western blot band intensity was analyzed using the ImageJ program. After
normalization against total Akt levels and b-actin levels, the compounds
enhanced Akt phosphorylation levels by 1.6- to 6.5-fold compared with DMSO
control.
(H) Candidate compounds promoted Flk1 expression in differentiatingmESCs.
Cells were analyzed on day 4 of differentiation by flow cytometry for
percentage of Flk1+. Expression levels were normalized to levels with DMSO.
See also Figure S6.
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Figure 6. Test of Selected Candidate Compounds in Vivo
(A–C) Representative images of retinal vasculature treated with DMSO, SST, and Dip. (A, A0, and A00) 0.5%DMSO. (B, B0, and B00) 10 mMSST. (C, C0, and C00) 10 mM
Dip. (A–C) Frontal view of retinal vasculature after removal of cornea and lens of Flk1-GFP transgenic adult eyes without flat mount. (A0–C00) Frontal view after flat
mount. (A00, B00, and C00) Higher magnification of A0, B0, and C0, respectively.
(D and E) Quantifications of vessel number and relative density per eye, respectively. p = 0.0216 for SST and p = 0.022 for Dip against control in vessel numbers.
p = 0.009 for SST and p = 0.025 for Dip against control in relative density.Cleaned embryos were combined and treated in 8 ml Holtfreter’s solution
containing 3 mg/ml pronase for 8 min. This allowed removal of chorions after
several washes with Holtfreter’s solution. Dechorinated healthy embryos were
transferred to a clean tissue culture dish. To produce enough cells for one
384-well plate, 1,600 embryos should be prepared.
The embryos were then bleached in 0.04% sodium hypochlorite (Cat.
23930-5; Aldrich) for exactly 3 min followed by five washes in PBS. The
embryos were then transferred to a 1.5 ml Eppendorf tube, excess PBS was
removed, and the embryoswere homogenized with blue pestles (Fisher Scien-
tific). After homogenization, cell aggregates were transferred to a tube con-702 Cell Reports 2, 695–704, September 27, 2012 ª2012 The Authortaining 6 ml of 0.05% trypsin (Invitrogen) and incubated at 37C for 10 min.
Then an equal volume (6 ml) of medium containing 10% FBS was added to
the tube to stop trypsin digestion. The cell suspension was gently mixed and
then centrifuged at 800 rpm for 4–6 min at 4C (Allegra 25R centrifuge;
Beckman). The cell pellets were resuspended in the culture medium (18 ml
for every 1,600 embryos) and 40 ml cell suspension was distributed into each
of 384 wells using a multichannel pipette. Cells were grown at 32C without
CO2. At day 5, fluorescence of cultured tg(kdrl:gfp) cells was imaged using
the ImageXpress Micro Screening System (Molecular Devices) equipped
with LHS-H100P-1 camera (Nikon, Japan). The image of each well wass
analyzed with Angiogenesis Tube Formation (RD-1) of High Content Image
Processing Software to generate data regarding the tube length and branch
points (MetaXpress; Molecular Devices).
Endothelial Proliferation and Migration Assays
HUVECswere purchased from Invitrogen (C-015-5C) and cultured in the endo-
thelial cell growth medium (MV2 plus complete supplement, C-22221 and
C-39221; PromoCell) at 37C and 5% CO2. For the proliferation assay,
HUVECs were seeded at a density of 6 3 103 cells/well in 96-well plate in
normal growth medium for 24 hr. The medium was then changed to 0.5%
(v/v) FBS containing MV2 for serum starvation for 24 hr. Cells were stimulated
with hVEGF165 (#8065; Cell Signaling) and small molecules for 72 hr (Holmes
et al., 2010), and the number of viable cells was determined using the MTT
assay (Twentyman and Luscombe, 1987). For the MTT assay, 2 ml fresh
MTT (M2128; Sigma) solution was prepared per 96-well plate at 5 mg/ml in
PBS, and 20 ml MTT solution was added to each well. The plates were put
on a shaker at 150 rpm for 5 min to mix the MTT thoroughly into the media.
Plateswere incubated (37C, 5%CO2) for 1–5 hr to allow theMTT to bemetab-
olized. Themedia were discarded, and formazan (MTTmetabolic product) was
dissolved in 200 ml DMSO. The plates were put on a shaker at 150 rpm for 5min
to mix the formazan thoroughly into the solvent. Optical density was recorded
at 570 nm and subtracted with background at 630 nm. Optical density is
directly correlated with cell quantity. For the migration assay, HUVECs were
seeded at a density of 5 3 104 cells/well in 24-well plate in normal growth
medium for 48 hr. The media were then changed to 1% (v/v) FBS containing
MV2 for serum starvation for 24 hr. A scratch was introduced to the cell mono-
layer using a sterile 200 ml pipette tip followed by incubation with hVEGF165
(#8065; Cell Signaling) and small molecules for 16–24 hr (Holmes et al.,
2010). The migration distance was measured in micromolars for comparison.
Akt Phosphorylation Assays by Western Blotting Analysis
For Akt phosphorylation assays, 5 3 105 HUVEC cells/well were seeded in
a six-well plate and cultured in the medium MV2 plus supplement for 24 hr,
followed by 12 hr starvation in the medium MV2 plus 0.5% FBS. After starva-
tion, cells were treated with DMSO or compounds in the samemedium for 8 hr,
followed by total protein preparation. Phospho-Akt (S473) antibody and total
Akt (C67E7) antibody were purchased from Cell Signaling (p-Akt #9271 and
Akt [pan] #4691), and protein gels were purchased from Thermo Scientific
(Cat. 25200-25244). The Akt kinase assay was performed according to
protocols provided by the manufacturers.
Growth and Differentiation of mESCs
iER71 mESCs were maintained in an undifferentiated state on a mitomycin C
inactivated CF1MEF feeder layer. Cells were grown in KO-DMEM (Invitrogen),
15% FBS (Hyclone), 13NEAA, 13 penicillin/streptomycin/L-glutamine, 55 mM
b-mercaptoethanol (all Invitrogen), and 1,000 U/ml LIF (Millipore). Differentia-
tion was induced by plating 1 3 105 cells/well of a six-well plate in Iscove’s
modified Dulbecco’s medium (Invitrogen), 15% FBS (Hyclone), 13 penicillin/
streptomycin/L-glutamine and 55 mM b-mercaptoethanol (both Invitrogen),
and 50 mM ascorbic acid. Compounds were added on day 2 of differentiation.
Flow Cytometry
Cells were harvested by 0.25% trypsin digestion on day 4 of differentiation.
Immunolabeling was performed with 1:100 PE conjugated anti-mouse
Flk1 (KDR; BD-PharMingen) in PBS with 1% BSA and analyzed on a BD
LSRFortessa cell analyzer.
Retinal Angiogenesis Assay
Individual flk1-GFP transgenic adult fish (14 months old) were incubated in
60 ml fish water containing 0.5% DMSO and selective compounds or only
0.5% DMSO for 72 hr, followed by eye dissection under a Zeiss dissection
microscope (Cao et al., 2010). Images were obtained and analyzed on an
Axioplan 2 Zeiss microscope with fluorescence. Blood vessel branches within
a circle with a radius of 90 mm from the optic disc were counted with the use
of OpenLab software. Total vascular density was measured as percentage
of area covered by fluorescent vessel within the same circle centering at the
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